Jason Cota & William “Barry” Inman – Advanced Infectious Disease Pharmacology Course
$44.00
Digital Download: You will receive a download link via your order email
Should you have any questions, please contact us: [email protected]
Jason Cota & William “Barry” Inman – Advanced Infectious Disease Pharmacology Course
In the new world where COVID-19 is taking center stage, having solid infectious disease pharmacology knowledge is essential for your patient care.
If you don’t know the core principles, how can you identify when something is new, different or strange? And missing a key finding in a patient can be the difference between a treated infection and sepsis.
This carefully curated online course covers proper prescribing, patient education, and monitoring procedures for a variety of drug regimens used to treat common acute and chronic infectious diseases.
Jason and Barry not only teach the foundations of infectious disease pharmacology, but ground them in real-life experiences…
PLUS, get special bonus content on COVID-19 vaccines and treatments!
This self-paced video training will give you the skills to:
- Confidently select the best empiric therapy before culture data is available
- Narrow antibiotic coverage at the right time like a seasoned pro
- Expertly reduce bacterial resistance — your colleagues will think you wrote the IDSA guidelines!
- Interpret culture and sensitivity results to select the most narrow and targeted antibiotic therapy
- Earn up to 16.25 CE hours – INCLUDING up to 7.3 pharmacology CE hours
- … And so much more!
Here’s what you’ll cover in this state-of-the-art online training course:
— with Jason Cota, PharmD, MS
- Drug classes
- Pharmacokinetic Properties
- Concentration-dependent killing
- Time-dependent killing
- Post-antibiotic effect
- Common interactions with other drugs
- Define true allergy
- Sulfonamide antibiotics vs non-antibiotics
- Penicillin — Cephalosporin cross-sensitivity
- Differentiation
- Normal flora
- Common pathogens
- Trends
- Mechanisms of resistance
- Contributing factors
Community versus Hospital Acquired
- Differentiating between CA- and HA-MRSA
- Current clinical practice guidelines
- Pharmacologic management
- Extended Spectrum Beta-Lactamase (ESBL)
- What are ESBLs
- Pharmacologic management
- Carbapenem-Resistant Enterobacteriaceae (CRE)
- What are CREs
- Pharmacologic management
- Bacterial Etiology, Signs and Symptoms and Diagnosis
- Cystitis and pyelonephritis
- Complicated and uncomplicated
- UTIs in pregnancy
- Treatment (IDSA Guideline Treatment Algorithm)
- Acute
- Recurrent and relapse
- Risk factors
- Pharmacology management
- Fecal Transplantation
- Probiotics literature review
- Bacterial etiology
- Diagnosis
- Typical vs. atypical
- Treatment (IDSA/ATS Guidelines) and monitoring
- Outpatient vs. inpatient
- Empiric treatment
- Bacterial etiology
- Treatment (IDSA/ATS Guidelines)
- Sinusitis and pharyngitis
- Etiology (Viral vs. Bacterial)
- Treatment
- Cellulitis
- Bacterial etiology
- Strep. vs. Staph. vs. MRSA
- Signs & symptoms
- Treatment (IDSA Guidelines)
- Clinical features
- Diagnosis
- Pharmacology management
- Types of Vaccines
- General recommendations
- Contraindications & precautions
— with William “Barry” Inman, BA-BS, CIC
- Catheter-Associated Urinary Tract Infections
- Surgical Site Infections
- Ventilator-Associated Pneumonias
- Non-ventilator Associated Infections (overlooked HAI)
- Central-Line Associated Bloodstream Infections
- Carbapenem-resistant enterobacteriaceae
- Clostridium difficile
- Methicillin-resistant staphylococcus aureus
- Vancomycin resistant enterococcus
- Acinetobacter baumannii
- Avian vs. swine vs. seasonal influenza
- H1N1 pandemic results
- When to treat? When not to treat?
- Treatment with anti-virals and antibiotics
- New vaccines for flu
- Zoster/shingles
- Pneumoccocal
- MMR, Tdap, etc.
- Ebola: What we learned
- Mosquito-borne (“Zika”, Dengue, Chickungunya, West Nile)
- Tick-borne (Lyme and Babesia)
- Cryptosporidiosis
- Hepatitis B
- Vaccination protocol for healthcare personnel
- Staff follow-up after significant exposures
- Treatments for persons chronically infected
- Outbreaks in healthcare
- Hepatitis C
- Treatment “cures” in 12-24 weeks
- Outbreaks in healthcare-dialysis settings
- HIV/AIDS
- New one pill daily treatment
- Healthcare exposure and appropriate prophylaxis
- Today’s best approaches to treatment
- Skin testing vs. blood test for exposure
- Follow-up guidelines for healthcare workers conversion testing
Jason Cota, PharmD, MS, is an associate professor and the vice chair of the Pharmacy Practice Department at the University of the Incarnate Word Feik School of Pharmacy. He also has over 10 years of experience practicing as an infectious diseases clinical pharmacist at the San Antonio Military Medical Center, where he is a credentialed provider with prescriptive authority.
Click here for information about Jason Cota
William “Barry” Inman, BA-BS, CIC, has 31 years of experience as an epidemiologist. He works for the Brevard County Health Department in Merritt Island, Florida and is a faculty member for Brevard Community College and the University of Central Florida teaching classes on infection control.
Sale Page: https://catalog.pesi.com/sales/hc_c_001348_pharminfectiousdiseases_organic-141055
Archive: https://archive.ph/wip/ezBKD
Reviews
There are no reviews yet.